(Q36758578)

16 August 2017

1 reference

title

Emerging drugs to treat Crohn's disease (English)

1 reference

16 August 2017

0 references

Gert van Assche

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Emerging Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

49-59

1 reference

Inflammatory Bowel Disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Mechanisms of disease: defensins in gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Frequency of glucocorticoid resistance and dependency in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.49

21 January 2018

Identifiers

DOI

10.1517/14728214.12.1.49

1 reference

16 August 2017

1 reference